FISH assay development for the detection ofp16/CDKN2Adeletion in malignant pleural mesothelioma
Open Access
- 30 June 2010
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 63 (7), 630-634
- https://doi.org/10.1136/jcp.2010.076794
Abstract
Aims To develop a fluorescence in-situ hybridisation (FISH) assay for detecting p16/CDKN2A deletion on paraffin tissue sections for use as an ancillary test to distinguish reactive from malignant mesothelial proliferations. Method Dual-colour FISH for p16/CDKN2A and chromosome 9 (CEP-9) was performed on 11 benign mesothelial proliferations and 54 malignant pleural mesothelioma (MPM) cases to establish cut-off values for p16/CDKN2A deletion. A third MYC probe was used to verify cases showing homozygous deletion. Eight equivocal biopsies were used for assay testing. Results Cut-off values for p16/CDKN2A deletion were calculated based on FISH signalling patterns obtained from the benign controls (mean percent nuclei plus three standard deviations). Hemizygous deletion was defined as >44% of nuclei showing the hemizygous (one p16/CDKN2A, two CEP-9 signals) or >15% of nuclei showing the monosomy (one p16/CDKN2A, one CEP-9 signal) deletion patterns. None of the benign cases showed a homozygous deletion pattern (no p16/CDKN2A, at least one CEP-9 signal). In the malignant cases, the percentage of nuclei showing homozygous deletion ranged from 1% to 87%. Therefore, the cut-off value for homozygous deletion was defined as >10%. P16/CDKN2A deletion was detected in 61% (33/54) of MPM cases. Among the equivocal biopsies, four showed homozygous and one showed hemizygous p16/CDKN2A deletion. Age over 60 years, asbestos exposure and p16/CDKN2A deletion were associated with a worse prognosis. Conclusion Distinction between benign and malignant mesothelial proliferations can be diagnostically challenging. FISH for p16/CDKN2A deletion is a useful test for confirming the diagnosis of MPM.Keywords
This publication has 27 references indexed in Scilit:
- Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomasVirchows Archiv, 2008
- The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2Histopathology, 2003
- Cadherins, catenins and APC in pleural malignant mesotheliomaThe Journal of Pathology, 2003
- Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.2003
- Codeletion of p15 and p16 in primary malignant mesothelioma.1995
- p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.1994
- p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimensHuman Pathology, 1994
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin‐fixed paraffin sectionsThe Journal of Pathology, 1992
- Immunoreactivity for the β chain of the platelet‐derived growth factor receptor in malignant mesothelioma and non‐neoplastic mesotheliumThe Journal of Pathology, 1992